synthesis directly and limit any subsequent increase in total body levels of potassium,5 but potassium-mediated mineralocorticoid production by the adrenal requires the presence of angiotensin II and does not occur during converting-enzyme inhibition.6 Consequently, the excretion of potassium becomes notably impaired during captopril therapy, and therefore, serum potassium concentration varies directly with changes in dietary potassium. Hyperkalemia may result if potassium intake is increased [either by the administration of prescribed potassium supplements or by the use of potassium-containing salt substitutes) or the renal excretion of potassium is further impaired [by treatment with potassium-sparing diuretics or by decreases in glomerular filtration rate).2 On the other hand, hypokalemia can occur in patients being treated with diuretic drugs if the renal disposal of potassium is restored by the withdrawal of converting-enzyme ind hibition and dietary potassium is not supplemented. Although in most cases changes in serum potassium concentration are small, our findings indicate that in some patients, hypokalemia or hyperkalemia may be sufficiently severe to cause cardiac arrest. Hence, we recommend close attention to and reevaluation of dietary potassium intake and prescribed potassium supplementation whenever treatment with convertingenzyme inhibitors is instituted or discontinued. stenosis (MS). This report describes balloon angioplasty in 2 children with congenital MS and in 1 adolescent with rheumatic MS.
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Case 1: P.P., an l&year-old woman with rheumatic MS, underwent cardiac catheterization on Ianuary 28, 1984 because of severe dyspnea and chest pain. Catheterization revealed severe MS, mild aortic stenosis and regurgitation and mild pulmonary hypertension. After the patient was informed that balloon dilation of the mitral valve was an experimental but potentially therapeutic alternative to surgical mitral commissurotomy, she consented to the procedure. On February 6.1984, using the percutaneous femoral approach, predilation hemodynamics and angiography were performed (Table I, eter with a Z&mm balloon (Medi-Tech) was positioned across the mitral valve. The balloon was inflated to 4 atm for less than IO seconds. During the procedure left ventricular and pulmonary artery pressures and heart rate were continuously monitored. The angioplasty catheter was then exchanged for the wedge catheter. Complete right-and left-sided heart hemodynamic values and a repeat left ventricuJar angiogram indicated a reduction in left atrial and pulmonary artery pressure without an increase in mitral regurgitation (Table I, Fig. 1 ). The patient was discharged from the hospital the next day. On her most recent clinic visit, 15 months after angioplasty, she reported a definite improvement in her symptoms. Her exercise tolerance on the treadmill (Bruce protocol) improved from 9 minutes to 11.5 minutes, with an increase in maximal heart rate response (80 to 171 beats/min vs 86 to 184 beats/minj. In addition, the chest pain, which had been present during stages II and III of the prior treadmill, was no longer observed. She has also continued to show hemodynamic improvement of MS as assessed by Doppler examinations under resting conditions and similar heart rate (Table II) .
Case 2: B.S., a l&year-old girl with a repaired coarctation of the aorta, had mild subaortic stenosis and severe congenital MS. Because of severe dyspnea, March 20, 1985 she underwent cardiac catheterization, which revealed severe MS and pulmonary artery hypertension (Table I] , Balloon angioplasty was performed. The technique was identical to that described for case I, except that a E-mm angioplasty balloon was used. Two months after angioplasty there has been mild improvement in symptoms and continued hemodynamic improvement documented on Doppler examination3 under resting conditions and a similar heart rate (Table II) .
Case 3: K.K., a .&year-old boy, had severe congenital MS, coarctation of the aorta, patent ductus, left ventricular hypoplasia, subaortic stenosis and severe pulmonary artery hypertension. Because of severe exercise intolerance and differential cyanosis, mitral valve angioplasty was attempted on October 27, 1984. Using the aforementioned technique, a 12-mm angioplasty catheter was advanced across the atrial septum and into the left atrium. The catheter could not be advanced across the mitral valve, and angioplasty could not be performed. Two months after the attempted angioplasty a large left atrial thrombus was identified and because of increasing symptoms surgical removal of the thrombus was attempted. The child, however, died from sepsis 2 months later. We do not know if the left atria1 thrombus was related to the transseptal puncture, angioplasty balloon manipulation, low blood flow or polycythemia.
To our knowledge, this is only the second report of the use of balloon angioplasty to treat rheumatic MS and the first report of its use to treat congenital MS. In the 2 patients in whom we successfully performed mitral valvuloplasty, left atria1 and pulmonary artery pressures decreased significantly and mitral valve area increased significantly, without any increase in mitral regurgitation. In addition, follow-up of 2 and 15 months has shown both clinical and hemodynamic improvement. Our results are similar to those previously reported by Inoue et al3 and suggest that balloon angioplasty is feasible in both rheumatic and congenital MS. Despite these results 2 additional technical obstacles must still be overcome. First, although for an individual patient the ideal size of the angioplasty balloon is unknown, based on our experience with pulmonary stenosis4 we believe a balloon approximately the size of the mitral anulus should be used. Only a 2O-mm balloon was used in case 1, since this was the largest size available. Had we used a larger balloon or, possibly 2 balloons side-by-side, a better result might have been achieved. Second, it was impossible to manipulate the large stiff angioplasty balloon across the stenotic mitral valve in case 3. It is conceivable that either with the aid of a large (12 to 15Fr) sheath or using a precurved catheter that it might have been possible to perform angioplasty in this patient. Although mitral valve angioplasty is, at present, an experiinental procedure, if these technical problems can be solved, it is likely that balloon angioplasty may be an alternative for selected patients with MS to surgical mitral commissurotomy.
